title: Rosuvastatin and ciprofibrate in the treatment of dyslipidemia in patients with HIV.
abstract: BACKGROUND
  Dyslipidemia secondary to highly active antiretroviral therapy in patients with HIV is associated with a significant increase in cardiovascular morbidity and mortality due to atherosclerotic disease, requiring, thus, immediate and effective treatment.
  
  
  OBJECTIVE
  To demonstrate the effectiveness and safety of rosuvastatin and ciprofibrate in the treatment of dyslipidemia associated with highly active antiretroviral therapy in patients with HIV.
  
  
  METHODS
  Three hundred and forty-six patients with dyslipidemia underwent pharmacological treatment as follows: 200 patients with hypertriglyceridemia received ciprofibrate (Group I); 79 patients with hypercholesterolemia received rosuvastatin (Group II); and 67 patients with mixed dyslipidemia received ciprofibrate associated with rosuvastatin (Group III). The lipid profile was assessed before and after the lipid-lowering treatment, and the Wilcoxon test was used for statistical comparison. Liver transaminases and creatine phosphokinase were measured to assess liver and muscle toxicity.
  
  
  RESULTS
  The serum concentrations of triglycerides and total cholesterol were significantly lower than those obtained before the lipid-lowering treatment in the three experimental groups (p < 0.002). A significant increase in HDL-cholesterol was observed in Groups I and III (p < 0.002). In Groups I and II, LDL-cholesterol was significantly lower (p < 0.001). None of the patients experienced elevations in transaminases or creatine phosphokinase to significantly toxic levels.
  
  
  CONCLUSIONS
  The results of this study show that ciprofibrate and rosuvastatin or a combination of both can be considered an effective, safe and well-tolerated lipid-lowering treatment for patients with AIDS on highly active antiretroviral therapy.
authors.affiliation: Faculdade de Medicina, Universidade Federal de Mato Grosso do Sul, Campo Grande, MS, Brasil. hdomingos66@hotmail.com
authors.forename: Hamilton
authors.initials: H
authors.lastname: Domingos
authors.forename: Rivaldo Venâncio da
authors.initials: RV
authors.lastname: Cunha
authors.forename: Anamaria Mello Miranda
authors.initials: AM
authors.lastname: Paniago
authors.forename: Albert Schiaveto de
authors.initials: AS
authors.lastname: Souza
authors.forename: Renata London
authors.initials: RL
authors.lastname: Rodrigues
authors.forename: João Américo
authors.initials: JA
authors.lastname: Domingos
mesh_terms: D000328:Adult; D023241:Antiretroviral Therapy, Highly Active / Q000009:adverse effects*; D002318:Cardiovascular Diseases / Q000139:chemically induced; D002784:Cholesterol / Q000097:blood; D050171:Dyslipidemias / Q000139:chemically induced / Q000188:drug therapy*; D005260:Female; D058607:Fibric Acids / Q000627:therapeutic use*; D005464:Fluorobenzenes / Q000627:therapeutic use*; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011743:Pyrimidines / Q000627:therapeutic use*; D012307:Risk Factors; D000068718:Rosuvastatin Calcium; D018709:Statistics, Nonparametric; D013449:Sulfonamides / Q000627:therapeutic use*; D016896:Treatment Outcome; D014280:Triglycerides / Q000097:blood
chemical_list: D058607:Fibric Acids; D005464:Fluorobenzenes; D000960:Hypolipidemic Agents; D011743:Pyrimidines; D013449:Sulfonamides; D014280:Triglycerides; D000068718:Rosuvastatin Calcium; D002784:Cholesterol; C019304:ciprofibrate